 |
Promotion Builds on Successful 13-Year Career at PRA Group, Most Recently Overseeing Record Portfolio Investments as Global Investments Officer
NORFOLK, Va., June 19, 2025 /PRNewswire/ -- PRA Group, Inc. (Nasdaq: PRAA), a global leader in acquiring and collecting nonperforming loans, has promoted Owen James to president of PRA Group Europe. As president of PRA Group Europe, James will provide leadership across 15 markets in Europe, Canada and Australia. He will also be responsible for overseeing portfolio investments across Europe, while building on the continued profitability of the European business.
James will report to President and CEO Martin Sjolund, who he succeeds.
"I am honored to serve as president of PRA Group Europe and to build upon the success of our European business. I am excited to continue working with our senior leadership team in this new capacity to execute our strategy and further strengthen our company's presence in key strategic markets across Europe," said James.
Over the past seven years, PRA Group's European business has delivered strong results and become a significant driver of the company's performance, with more than $3 billion successfully invested in portfolios across Europe.
James has more than 30 years of experience in financial services. He joined PRA Group 13 years ago, through the company's acquisition of Mackenzie Hall Holdings in 2012. James performed various leadership roles in PRA Group's European business before serving as global investments officer, where he oversaw the company's global investment strategy. Prior to joining PRA Group, he worked for more than 15 years in a variety of senior roles at Intrum, a major European debt servicer and buyer.
"Having worked with Owen for more than 10 years, he is the ideal person to lead PRA Group Europe to continued success. Owen has deep investment experience, strong operational know-how and is a highly respected leader in the global nonperforming loan industry. I know he will build upon PRA Group Europe's track record of success as one of the most efficient debt-buying operations," said Sjolund.
About PRA Group
As a global leader in acquiring and collecting nonperforming loans, PRA Group, Inc. returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe and Australia. With thousands of employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt. For more information, please visit www.pragroup.com.
Media Contact:
Giovanna Genard
Vice President, Global Communications and External Affairs | Marketing Leader
(757) 282-3343
Giovanna.Genard@PRAGroup.com
Investor Contact:
Najim Mostamand, CFA
Vice President, Investor Relations
(757) 431-7913
IR@PRAGroup.com
Promotion Builds on Successful 13-Year Career at PRA Group, Most Recently Overseeing Record Portfolio Investments as Global Investments Officer
NORFOLK, Va., June 19, 2025 /PRNewswire/ -- PRA Group, Inc. (Nasdaq: PRAA), a global leader in acquiring and collecting nonperforming loans, has promoted Owen James to president of PRA Group Europe. As president of PRA Group Europe, James will provide leadership across 15 markets in Europe, Canada and Australia. He will also be responsible for overseeing portfolio investments across Europe, while building on the continued profitability of the European business.
James will report to President and CEO Martin Sjolund, who he succeeds.
"I am honored to serve as president of PRA Group Europe and to build upon the success of our European business. I am excited to continue working with our senior leadership team in this new capacity to execute our strategy and further strengthen our company's presence in key strategic markets across Europe," said James.
Over the past seven years, PRA Group's European business has delivered strong results and become a significant driver of the company's performance, with more than $3 billion successfully invested in portfolios across Europe.
James has more than 30 years of experience in financial services. He joined PRA Group 13 years ago, through the company's acquisition of Mackenzie Hall Holdings in 2012. James performed various leadership roles in PRA Group's European business before serving as global investments officer, where he oversaw the company's global investment strategy. Prior to joining PRA Group, he worked for more than 15 years in a variety of senior roles at Intrum, a major European debt servicer and buyer.
"Having worked with Owen for more than 10 years, he is the ideal person to lead PRA Group Europe to continued success. Owen has deep investment experience, strong operational know-how and is a highly respected leader in the global nonperforming loan industry. I know he will build upon PRA Group Europe's track record of success as one of the most efficient debt-buying operations," said Sjolund.
About PRA Group
As a global leader in acquiring and collecting nonperforming loans, PRA Group, Inc. returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe and Australia. With thousands of employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt. For more information, please visit www.pragroup.com.
Media Contact:
Giovanna Genard
Vice President, Global Communications and External Affairs | Marketing Leader
(757) 282-3343
Giovanna.Genard@PRAGroup.com
Investor Contact:
Najim Mostamand, CFA
Vice President, Investor Relations
(757) 431-7913
IR@PRAGroup.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Experienced Leader Owen James Promoted to President of PRA Group Europe
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
